Screening Rate for Primary Aldosteronism Among Patients With Apparent Treatment-Resistant Hypertension: Retrospective Analysis of Current Practice
- 27 November 2021
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 28 (3), 271-275
- https://doi.org/10.1016/j.eprac.2021.11.085
Abstract
No abstract availableKeywords
Funding Information
- National Center for Advancing Translational Sciences (UL1TR002494)
- University of Minnesota
- National Institutes of Health (P30 CA77598)
This publication has 29 references indexed in Scilit:
- Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseHypertension, 2014
- Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice NetworkHypertension, 2013
- Incidence and Prognosis of Resistant Hypertension in Hypertensive PatientsJournal of the American College of Cardiology, 2012
- Confirmatory testing in primary aldosteronism: extensive medication switching is not needed in all patientsActa Endocrinologica, 2012
- Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT)Journal of Hypertension, 2011
- Clinical Features of 8295 Patients With Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure MonitoringHypertension, 2011
- Cardiovascular Outcomes in Patients With Primary Aldosteronism After TreatmentArchives of Internal Medicine, 2008
- Evidence for an increased rate of cardiovascular events in patients with primary aldosteronismJournal of Invasive Cardiology, 2005
- Low-renin status in therapy-resistant hypertensionJournal of Hypertension, 2004
- Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe regionJournal of Human Hypertension, 2003